Apollomics (APLM) Short Interest Ratio & Short Volume

Short interest is the volume of Apollomics shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 81,900 shares of APLM short. 0.20% of Apollomics' shares are currently sold short. Learn More on Apollomics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.20% of Apollomics' floating shares are currently sold short.

Apollomics saw a decline in short interest in May. As of May 15th, there was short interest totaling 81,900 shares, a decline of 32.6% from the previous total of 121,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Apollomics currently has issued a total of 89,500,000 shares. Some of Apollomics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Apollomics currently has a public float of 41,600,000 shares.

0.20% of Apollomics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Apollomics: Enlivex Therapeutics Ltd. (1.24%), Aprea Therapeutics, Inc. (0.68%), Bolt Biotherapeutics, Inc. (8.82%), ImmunoPrecise Antibodies Ltd. (0.93%), JanOne Inc. (2.92%), Viracta Therapeutics, Inc. (2.42%), Oncternal Therapeutics, Inc. (0.87%), Biora Therapeutics, Inc. (3.85%), Spruce Biosciences, Inc. (0.30%), Lisata Therapeutics, Inc. (0.16%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling APLM is an investing strategy that aims to generate trading profit from Apollomics as its price is falling. APLM shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Apollomics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of APLM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLM, twice per month. The most recent reporting period available is May, 15 2024.